{"product_id":"lucivalgan-valganciclovir","title":"LuciValgan (Valganciclovir)","description":"\u003ch2\u003eAbout Valganciclovir\u003c\/h2\u003e\u003cp\u003eValganciclovir is an antiviral medication used to treat cytomegalovirus (CMV) infection in those with HIV\/AIDS or following organ transplant (eg, heart, kidney, or kidney-pancreas transplant).\u003csup id=\"cite_ref-AHFS2016_3-0\" class=\"reference\"\u003e\u003c\/sup\u003e\u003c\/p\u003e\u003cp\u003eIt is often used long term as it only suppresses rather than cures the infection.\u003c\/p\u003e\u003ch3\u003eCytomegalovirus Retinitis\u003c\/h3\u003e\u003cp\u003eIndicated for treatment of CMV retinitis in patients with AIDS\u003c\/p\u003e\u003cp\u003eInduction dose: 900 mg PO q12hr for 21 days\u003c\/p\u003e\u003cp\u003eMaintenance dose: Following induction treatment, or in adults with inactive CMV retinitis, 900 mg PO qDay\u003c\/p\u003e\u003ch3\u003eCMV Colitis or Esophagitis in HIV-Infected Patients (Off-label)\u003c\/h3\u003e\u003cp\u003eTreat initially with ganciclovir 5 mg\/kg\/dose IV q12hr; once therapy is tolerated, change to valganciclovir 900 mg PO q12hr for 21-42 days or until signs and symptoms have resolved\u003c\/p\u003e\u003ch3\u003eCMV Prevention in Solid Organ Transplant\u003c\/h3\u003e\u003cp\u003eIndicated for the prevention of CMV disease in kidney, heart, and kidney-pancreas transplant patients at high risk (donor CMV seropositive\/recipient CMV seronegative [D+\/R-])\u003c\/p\u003e\u003ch4\u003eKidney transplantation\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e900 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eBegin within 10 days of transplant until 200 days post-transplant\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eKidney-pancreas transplantation\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e900 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eBegin within 10 days of transplant until 100 days post-transplant\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHeart transplantation\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e900 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eBegin within 10 days of transplant until 100 days post-transplant\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003cp\u003eHepatic impairment: Safety and efficacy not established\u003c\/p\u003e\u003ch4\u003eRenal impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eCrCl 40-59 mL\/min: 450 mg PO q12hr (induction), THEN 450 mg qDay\u003c\/li\u003e\n\u003cli\u003eCrCl 25-39 mL\/min: 450 mg PO qDay (induction), THEN 450 mg q2days\u003c\/li\u003e\n\u003cli\u003eCrCl 10-24 mL\/min: 450 mg PO q2days (induction), THEN 450 mg 2 times\/week\u003c\/li\u003e\n\u003cli\u003e\u0026lt;10 mL\/min (on hemodialysis): Not recommended\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eDosing Considerations\u003c\/h3\u003e\u003cp\u003eAdults should use tablets, not oral solution\u003c\/p\u003e\u003ch3\u003eLymphoproliferative Disorder (Orphan)\u003c\/h3\u003e\u003cp\u003eOrphan designation for treatment of post-transplant lymphoproliferative disorder in combination with nanatinostat\u003c\/p\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797955866667,"sku":"RL3120241212s250","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-1289.jpg?v=1787022243","url":"https:\/\/xomeds.com\/products\/lucivalgan-valganciclovir","provider":"XOMEDS","version":"1.0","type":"link"}